Erythroplasia of Queyrat

WikiDoc Resources for Erythroplasia of Queyrat
Articles
Most recent articles on Erythroplasia of Queyrat Most cited articles on Erythroplasia of Queyrat Review articles on Erythroplasia of Queyrat Articles on Erythroplasia of Queyrat in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Erythroplasia of Queyrat Images of Erythroplasia of Queyrat Photos of Erythroplasia of Queyrat Podcasts & MP3s on Erythroplasia of Queyrat Videos on Erythroplasia of Queyrat
Evidence Based Medicine
Cochrane Collaboration on Erythroplasia of Queyrat Bandolier on Erythroplasia of Queyrat TRIP on Erythroplasia of Queyrat
Clinical Trials
Ongoing Trials on Erythroplasia of Queyrat at Clinical Trials.gov Trial results on Erythroplasia of Queyrat Clinical Trials on Erythroplasia of Queyrat at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Erythroplasia of Queyrat NICE Guidance on Erythroplasia of Queyrat NHS PRODIGY Guidance FDA on Erythroplasia of Queyrat CDC on Erythroplasia of Queyrat
Books
Books on Erythroplasia of Queyrat
News
Erythroplasia of Queyrat in the news Be alerted to news on Erythroplasia of Queyrat News trends on Erythroplasia of Queyrat
Commentary
Blogs on Erythroplasia of Queyrat
Definitions
Definitions of Erythroplasia of Queyrat
Patient Resources / Community
Patient resources on Erythroplasia of Queyrat Discussion groups on Erythroplasia of Queyrat Patient Handouts on Erythroplasia of Queyrat Directions to Hospitals Treating Erythroplasia of Queyrat Risk calculators and risk factors for Erythroplasia of Queyrat
Healthcare Provider Resources
Symptoms of Erythroplasia of Queyrat Causes & Risk Factors for Erythroplasia of Queyrat Diagnostic studies for Erythroplasia of Queyrat Treatment of Erythroplasia of Queyrat
Continuing Medical Education (CME)
CME Programs on Erythroplasia of Queyrat
International
Erythroplasia of Queyrat en Espanol Erythroplasia of Queyrat en Francais
Business
Erythroplasia of Queyrat in the Marketplace Patents on Erythroplasia of Queyrat
Experimental / Informatics
List of terms related to Erythroplasia of Queyrat

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3

Historical Perspective

• Erythroplasia of Queyrat was named after Louis Queyrat, a French dermatologist who was head of the dermatology service of l'Hôpital Ricord, a venereal hospital in Paris, now Hôpital Cochin.

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of Erythroplasia of Queyrat is characterized by squamous cell carcinoma in situ of the glans penis
• The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

• [Disease name] may be caused by either [cause1], [cause2], or [cause3].
• [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
• There are no established causes for [disease name].

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Erythroplasia of Queyrat is more commonly observed among patients aged 40 years old.

Gender

• Males areaffected with Erythroplasia of Queyrat.

Race

• There is no racial predilection for [disease name].
• [Disease name] usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

• Most common risk factor in the development of Erythroplasia of Queyrat are uncircumcised penis.

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• Symptoms of Erythroplasia of Queyrat may include the following:

• Red rash on the tip of the penis
• Irritation on the tip of the penis

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].
• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].
• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• The mainstay of therapy for Erythroplasia of Queyrat is imiquimod or 5-fluorouracil for several weeks to months.

Surgery

• Microscopic shaving (Mohs surgery) can be performed for patients with aggressive forms of Erythroplasia of Queyrat.

Prevention

• There are no primary preventive measures available for [disease name].
• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
• Once diagnosed and successfully treated, patients with [disease name] are followedup every [duration]. Followup testing includes [test 1], [test 2], and [test 3].